Elevated Plasma Plasminogen Activator Inhibitor-1 in CD36 Deficiency
- Hidekatsu Yanai, MD, PHD1,
- Hitoshi Chiba, MD, PHD2 and
- Kazuhiko Matsuno, MD, PHD2
- 1Department of Laboratory Medicine, Hokkaido University School of Medicine, Sapporo, Japan
- 2Department of Health Science, Hokkaido University School of Medicine, Sapporo, Japan
- Corresponding author: Dr. Hidekatsu Yanai, yanaih{at}jikei.ac.jp
CD36 is a fatty acid transporter expressed in various tissues including adipose, heart, and skeletal muscle tissues. The elevated fasting triglyceride levels,intermediate-density lipoprotein cholesterol levels, and postprandial hyperlipidemia observed in human CD36 deficiency have been suggested as being due to abnormal fatty acid metabolism and insulin resistance (1,2). Lipid abnormalities and insulin resistance in CD36 deficiency are atherogenic; however, the association between CD36 deficiency and atherosclerosis …
